AVROBIO Inc Aktie News

U.S. FDA hat TX2100 für HHT die Fast-Track‑Zulassung erteilt und den Investigational New Drug (IND)-Antrag für die Phase‑1b‑Studie mit TX2100 bei HHT-Patienten in den USA freigegeben. Die Topline-Ergebnisse der Phase‑1a‑Studie zeigten, dass Einzeldosensteigerungen von TX2100 bei gesunden erwachsenen Freiwilligen generell sicher und gut verträglich waren. Das Unternehmen plant, bis Ende 2026 ein...

WATERTOWN, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced the completion of enrollment for the APEX trial, a 24-week Phase 2 c...

WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced financial results for the first quarter ended March 31, 2026, and provi...

WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed Jessica Chutter to its Board of Directors, effective June 8, 2026.